Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) announced a collaborative agreement with Swanielle to explore the expansion of its SKNJCT-003 Phase 2 clinical study for the treatment of basal cell carcinoma in the Asia-Pacific...
Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch...
Elite Pharmaceuticals (OTCQB:ELTP) announced it has launched a generic version of Norco tablets, a combination of hydrocodone bitartrate and acetaminophen for pain management. The generic hydrocodone bitartrate and...
Profound Medical (NASDAQ:PROF; TSX:PRN) announced a definitive co-sales and co-marketing agreement with Siemens Healthineers (XETRA:SHL) pursuant to which the companies will commercialize a new MRI-guided prostate...
CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...
Perimeter Medical Imaging AI (TSX-V: PINK; OTC: PYNKF) highlighted the November 26, 2024 webinar entitled, “Clearer Margins. Greater Confidence. Exploring the Benefits of OTC”, sponsored by the American Society of...
Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it will unveil its third TULSA-AI software module, UA Alignment Assistant at the upcoming 110th Scientific Assembly and Annual Meeting of the Radiological Society...
MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...
IMUNON (NASDAQ: IMNN) announced the results of its end-of-Phase 2 meeting with the FDA supporting investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a 500...
Leede Financial launched coverage of Nanalysis Scientific (TSXV: NSCI) (OTCQX: NSCIF) with a “speculative buy” rating and C$0.90 target price. The stock closed at $0.365 on November 22. Nanalysis operates two distinct...
Ikonisys Group (Euronext Paris:ALIKO) announced that its subsidiary, Hospitex, has been awarded a public tender to supply the innovative Ikoniscope20 robotic microscope to the Department of Pathological Anatomy in...
Enveric Biosciences (NASDAQ:ENVB) announced the completion of preclinical pharmacokinetic (PK) studies of EB-003, which support its oral bioavailability and targeted non-hallucinogenic profile. EB-003 is a potential...